Compare Global X Cloud Computing ETF (CLOU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cloud Computing ETF vs Merck & Co., Inc. — how do they compare? Global X Cloud Computing ETF trades at $24.25, while Merck & Co., Inc. trades at $123.94 (market cap $298.31B). The key difference: Merck & Co., Inc. pays a 2.82% dividend while Global X Cloud Computing ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Global X Cloud Computing ETF nearer its low. Which is the better fit depends on your goals.
| CLOU | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $26.38 | $129.52 |
52-Week Low | $17.60 | $77.60 |
Market Cap | — | $298.31B |
Enterprise Value | — | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLOU trades at $24.11, up 1.49% with a bullish technical signal from moving averages. The ETF shows strong institutional interest in cloud computing exposure but faces mixed oscillators with RSI indicating overbought conditions. Recent news highlights both opportunity in underperforming tech sectors and concerns about cloud ETF performance trends.
The outlook balances cloud computing's growth potential against valuation concerns and sector volatility. Investment opportunity lies in AI-driven cloud adoption, while risks include competitive pressures and the ETF's historical underperformance compared to broader tech indices.
Merck (MRK) trades at $124.03, up 0.4% today, with a bullish technical signal and strong institutional interest. Recent earnings beats and a 67.57% analyst buy rating support momentum. The company's acquisition of Terns Pharmaceuticals, announced on April 7, 2026, aims to bolster its oncology pipeline, while a dividend of $0.85 per share is scheduled for July 2026.
Outlook remains positive with a consensus price target of $137.30, though risks include rising debt levels and competitive pressures. Revenue growth is steady, but net income is projected to decline in 2026, highlighting execution challenges amid strategic expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Cloud Computing ETF
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
